Dr Tiernan and his colleagues (August 2002 JRSM 1 ) found a significant correlation between the desire for death and depressive scores on the Hospital Anxiety and Depression Scale (HADS) in patients with terminal cancer, and concluded that treatment with antidepressants such as selective serotonin reuptake inhibitors (SSRIs) might improve their quality of life (QoL). Previous work with the HADS and other QoL questionnaires in patients with advanced colorectal cancer has shown that QoL impairment correlates more with immune activation than with serum tumour markers and tumour volume 2 . Furthermore, this immune response was associated with a reduction in serum tryptophan that correlated with worse QoL scores 3 . Therefore, impairment of QoL in advanced cancer may be due to immune-mediated depletion in tryptophan concentrations 4 . Since tryptophan is a precursor for serotonin in the brain and reduction in the latter may be associated with depression, treatment with SSRIs might be effective by raising cerebral serotonin concentrations 5 . Busy doctors may be spared the onerous task of reviewing these thousands of articles, since an extensive independent review has just been completed. The House of Lords Select Committee on Animals in Scientific Procedures concluded that 'On balance we are convinced that experiments on animals have contributed greatly to scientific advances, both for human medicine and for animal health. Animal experimentation is a valuable research method which has proved itself over time' and 'Toxicological testing in animals is at present essential for medical practice and the protection of consumers and the environment'.
Andy Huang
The UK Life Sciences Animal Science Group, which represents over 30 000 biomedical researchers, supports the ethical use of animals in developing new medicines and welcomes the Select Committee's recommendation of further efforts to develop alternatives to animals. 3 that ranks adverse drug reactions as the fourth leading cause of death in western hospitals. Menache concludes that since these drugs 'were all thoroughly tested on laboratory animals' such tests must be worthless.
In fact Lazarou et al. 3 is a meta-analysis of the adverse effects of a group of drugs which must include many (e.g. digitalis glycosides, NSAIDs, steroids, antidiabetics, antitumour agents and anticoagulants) 4 that were in use before the legislative requirements for animal experiments were introduced. Menache also overlooks the fact that the incidence of adverse effects has not changed over the past 30 years despite the introduction of new treatments for hypertension, peptic ulcer, arthritis and cancer and many other innovative medicines.
Anyway, preclinical animal studies are primarily designed to protect the phase I volunteers. During the subsequent phase II and phase III clinical investigations a candidate drug will generally be 'tested' on approximately 3000 humans (probably more than double the number of animals used for the preclinical work-up) before licensing.
We agree with Menache that individualized therapy is a desirable goal. The industry is moving in that direction, but it will be some time before the potential of pharmacogenomics is fully realized, and this will not, in itself, bring about a cessation of animal experiments. Virtually all veterinary drugs originate from human medicine, and for every species difference there are many more species similarities. So we will continue to rely upon animals to furnish us with information about mammalian biology and pathology and to protect our phase I subjects, as well as our patients, in the best tests that we can devise. It would be irresponsible not to.
J Botting R J Flower
British Pharmacological Society, Unit 16, Angel Gate, City Road,
London EC1V 2SG, UK
In his letter about animal experiments (August 2002 JRSM 1 ), Dr Menache remarks that 'The 3Rs approach (replacement, reduction and refinement) is already out of date'. As the surviving coauthor of the Three Rs 2 , I should like to comment on this.
Having thus dismissed all three Rs, Dr Menache proceeds immediately to recommend replacement (of animals by human cell culture). If he looks at the Proceedings of the first three World Congresses on the 3 Rs 3-5 , he will see that hundreds of scientists worldwide are making great efforts to develop new replacement methods. (The fourth Congress was held in New Orleans in August 2002.) In the testing of drugs and biologicals, the new replacement methods have to be validated by elaborate procedures before they can be accepted by the safety regulation authorities. Important work in this field is being done by ECVAM (the European Centre for the Validation of Alternative Methods), whose many valuable reports are regularly published in ATLA (Alternatives to Laboratory Animals).
Since Dr Menache approves of replacement, he presumably objects to reduction and refinement. But as long as there are animals in the laboratory, reduction is important because wasting animals is inhumane, unscientific and uneconomical; and refinement is vital because the infliction of pain or even mild distress is not only inhumane but has psychosomatic effects that seriously upset experimental results 6,7 . , is present at several sites other than the corpus cavernosum, and known effects of the consequent vascular smooth muscle relaxation include headache in 16%, facial flushing in 10%, and hypotension and dizziness in 2% of patients 2 . Second, in-vitro research suggests that sildenafil can inhibit PDE5-induced platelet aggregation 3 . Cerebrovascular haemorrhage is a recognized, albeit rare, side-effect and bleeding from oesophageal varices 4 and from haemorrhoids 5 has been described after use of sildenafil. In case 2 of Hicklin et al. the patient had been prescribed amlodipine. This drug is metabolized by the same enzyme (cytochrome p450) and could therefore affect the pharmacokinetics of sildenafil, rendering haemorrhage more likely.
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